Investors & Partners · SOULSKIPPER Limited
SOULSKIPPER combines mobile systems engineering with augmented reality, sensors, Big Data and real-time AI. NOMAD brings these capabilities together for on-site and remote applications. FABS AI is a separate wellness and research development. Investors can consider four connected fields with distinct development stages and business perspectives.
A modular case platform for communication, sensors and edge AI, with perspectives for municipalities, large enterprises, public civil protection and medical support. Historical trials provide experience; current configurations require separate assessment.
Explore this technology field →Smart glasses, remote support and AI-assisted training bring expertise to the point of use, spanning industrial and medical workflows and support for public authorities and specialists.
Explore this technology field →Own development of data processing and interfaces for sensors, video, audio and location data. SAP and Palantir form part of the described integration environment; this does not imply a current partnership with either provider.
Explore this technology field →A separate open-couch concept combining electromagnetic stimulation, sound and vibroacoustics. Investment steps concern prototyping, sensors and scientific evaluation; medical efficacy and approval are not assumed.
Explore this technology field →Investors and development partners are sought for clearly scoped projects across these four fields. Potential business models include modular systems, software licensing, project-specific integration, training and supporting services. Each project needs validation with target customers, development budgets and measurable milestones. An overall funding requirement and investment terms have not yet been defined.
NOMAD AI · Case development experience
Current development builds on earlier practical trials. The founder reports successful tests with Airbus in Hamburg, Pfizer in Freiburg and Germany's Federal Agency for Technical Relief (THW). These examples describe historical development experience.
A trial concerned quality control in door manufacturing. The founder reports successful testing.
The case was tested for AI-assisted final inspection after cleaning pharmaceutical cleanrooms. The founder reports a successful trial.
The founder reports another successful trial with THW in Germany involving its Freiburg office.
The founder describes high temperature, very high humidity and airborne chemicals as particular challenges for the tested case configuration.
Project accounts describe a special battery, selected displays and a custom construction using a special stainless-steel alloy. The founder reports that the case successfully withstood the trial conditions.
This concerns that configuration and those conditions, not general resistance to all chemicals or validation of other equipment and limits.
Medical research · Development experience
The latest major medical research project with substantial involvement by LJUBOMIR FILIPOVIĆ investigated foundations of AI-assisted wound detection and care. He reports involvement of one of Germany's largest care providers and Charité university hospital.
As Chief Developer, he was responsible for hardware and AI software implementation, working with scientists on tools to support care assistants and trained nursing staff caring for patients at home.
The aim was to capture images for diagnostic assessment, consult doctors through telemedicine and use AI to generate automated care documentation. Clinical judgement remained central.
His work included optical systems and specialised high-resolution cameras, connecting mobile hardware, image processing and remote medical support within the case's development history.
Context: these trial accounts come from the founder. Dated reports, measurement records and written confirmations were not provided for this preview. Named organisations are not presented as current SOULSKIPPER partners, customers or supporters. The experiences concern the case, not evidence of FABS AI effectiveness or validation.
Own software and integration work complements the device: AI-assisted knowledge transfer, remote support, real-time analysis and traceable documentation. Historical project experience in demanding environments provides a foundation. New applications in industry, medicine, public authorities or civil protection each need a defined task, appropriate access rights, a safety architecture and project-specific validation.
Potential investment steps include selecting a concrete pilot use case, assessing reusable own technology, building an integration demonstrator and running a verifiable pilot. Agreed software, integration or service offerings may follow. Scalability depends on architecture, data volumes, infrastructure and the requirements of each deployment.
A starting point for discussion
FABS AI is at an early stage. We seek partners to help build a research prototype, assess the technology and develop the business. The proposed model combines equipment, software and supporting services.
Capital requirements and investment terms are not yet fixed. Funding depends on priorities, including technical development and the costs of at least two potential patent applications for FABS AI. An early medical-device approval pathway requires additional testing, documentation and funding. Alternatively, investors could initially support a premium wellness offering without medical approval as the first market goal. Next steps should follow a transparent budget and milestone plan.
FABS AI · Business outlook
The proposed model includes FABS AI systems, additional software functions, training, maintenance and support for professional users. Licensing and strategic cooperation are also options.
These are planned business activities, not claims of existing revenue, signed customer contracts or achieved market readiness.
FABS AI · Scientific background
Research into electromagnetic stimulation, sound and mechanical vibration offers useful starting points, but no universal healing frequencies. Frequency, intensity, timing, duration and tissue matter. FABS AI draws on this work to develop its own investigations.
A systematic review of 92 publications on pulsed electromagnetic fields (PEMF) describes measurable responses in cell cultures. Responses depend on cell type and application parameters. Such laboratory findings inform research questions; they do not establish therapeutic effects in humans.
Clinical PEMF evidence varies by application. A knee osteoarthritis meta-analysis of nine randomised studies with 457 participants reports time-dependent improvements in some symptoms, but not consistently clear findings. Different protocols and high risk of bias limit firm conclusions. Statistical improvements may not translate into noticeable everyday benefits.
Repetitive transcranial magnetic stimulation (rTMS) targets specific brain regions with magnetic pulses. It is a distinct medical procedure with defined safety requirements. Findings and settings cannot simply be transferred to a whole-body couch. FABS AI is not equated with a clinically validated rTMS system.
A systematic review of whole-body vibration for non-specific back pain reports improvements in several studies but highlights varied applications and the need for standardised research. Results do not automatically apply to couch-based vibroacoustics. Sound, music, binaural beats and mechanical vibration are different approaches. Binaural beats arise perceptually from two tones presented separately to the ears; they are not a physically emitted low-frequency tone.
We investigate whether objective body signals can improve understanding of individual responses and support more targeted adaptation within predefined safety limits. Planned AI will evaluate several factors together, supported by a systematically built parameter and measurement database, rather than simply choosing one frequency.
This is a research goal, not an established advantage. Safety and potential therapeutic benefit require studies of the complete system. Cell-culture findings and other devices' results cannot replace them. Implementation details are discussed confidentially.
FABS AI · Tesla and Lakhovsky · Possible future research
Historical patents and third-party patent publications are research sources, not SOULSKIPPER intellectual property or evidence of efficacy. Applications for two own developments are being considered; filing or grant is not claimed here.
Nikola Tesla's resonant high-frequency circuits form part of electrical engineering history. Energy moves between a capacitor and a coil, producing rapid electrical oscillations. This background offers possible further research questions for FABS AI.
Georges Lakhovsky, an inventor working in France, offers another historical reference. His multiwave oscillator uses nested open rings of different sizes to produce several electromagnetic wavelengths. The technical idea is to excite different resonances together: conductive structures respond differently according to their construction.
FR732276A and US1962565A, granted in 1934, document this approach. US2351055A (1944) describes a tube-based construction for generating or conducting several wavelengths in a more compact device. The later publication EP2862596A1 also refers to Lakhovsky's multiwave antenna.
A possible FABS AI research question is how individual-frequency responses differ from responses to defined combinations. This connects historical technology with planned individual body-signal analysis. It is our interpretation for possible future research, not a confirmed FABS AI function or effect.
FABS AI is conceived as an independent platform. Copper coils generate time-varying electromagnetic fields, speakers produce sound and transducers deliver mechanical vibration through the couch. Their programmable coordination and assessment alongside body signals may offer development value through individual response analysis and controlled adaptation under human supervision.
Electrical and acoustic frequencies differ: the same numerical frequency does not make an electromagnetic field equivalent to a sound wave. FABS AI is therefore not the historical high-frequency multiwave oscillator. Tesla and Lakhovsky provide inspiration; recreating their devices is not the development goal.
Lakhovsky's historical biological resonance and therapeutic ideas are treated as hypotheses. Patents do not replace clinical evidence. Adopting his device construction is not decided; extensions would undergo separate safety, measurement and third-party rights assessment.
Sources: Multiwave oscillator, FR732276A ↗ · Multiple wavelengths, US1962565A (1934) ↗ · Tube construction, US2351055A (1944) ↗ · Later reference, EP2862596A1 ↗
The initial focus is electromagnetic fields, sound and felt vibration. Body-signal recording and AI analysis are intended to investigate individual responses and adapt applications within predefined programme limits. These components are the proposed focus of the first research prototype.
The proposed FABS AI couch combines several stimulation methods. Multimodal here means bringing electromagnetic fields, sound and mechanical vibration into one research platform.
For investors, the opportunity concerns an integrated platform of hardware, control and analysis. Based on thorough patent searches already conducted, the founder considers the likelihood of obtaining patents for two distinct FABS AI developments very high. A patent attorney has not yet been engaged; specialist review and preparation of applications are planned for the next investor-funded development round.
Resonant high-frequency fields could become an additional research direction. They are not a confirmed part of the first prototype. A later stage would separately assess feasibility, safety and possible medical benefit.
Historical patents describe electrotherapeutic devices with Tesla coils; newer publications cover Tesla coils for cell stimulation and frequency-controlled therapy devices. They are relevant prior-art references, not scientific evidence of effectiveness.
Before developing a high-frequency extension, detailed patent review is planned, covering claims, current protection and third-party rights. Patentability and freedom to implement without infringing others' rights are separate questions. These documents are research starting points, not a substitute for review.
Patent references: Tesla: high-frequency currents, US568180A (1896) ↗ · Historical electrotherapeutic device, US1012326A ↗ · Cell therapy or stimulation device, DE112020006034B4 ↗ · Frequency-controlled therapy device, WO2015007840A1 ↗
FABS AI product concept, visualisations, development direction and proposed business model. NOMAD has a separate development history documented by historical photographs.
Building and testing a research prototype, technical validation and initial scientific studies. Available materials do not establish completion of these steps.
Cost model, funding, schedule, measurable milestones and possible investment or cooperation terms.
FABS AI planning involves successive stages, with scope, sequence and funding agreed against specific development goals.
No specific funding sum is fixed. It will be based on costs, priorities and agreed milestones.
Collaboration
FABS AI seeks investors, strategic and development partners, and potential licensees. Beyond funding, this means collaboration from concept to validated technology platform.
NOMAD AI focuses on its own mobile applications. Discussions are separate; FABS funding plans do not automatically apply to NOMAD AI.
Confidential discussion
Protecting technology, brand, design and know-how is part of planned company development. Rights are sought; granted patents or completed registrations are not claimed here.
Public disclosure before filing can jeopardise novelty in Europe, which lacks a general novelty grace period unlike the USA under certain conditions. We therefore reserve detailed FABS AI and NOMAD AI information for serious investors and prospective partners in personal discussions under agreed confidentiality. Protection strategy and financing terms are also confidential. Medical applications remain a long-term perspective.
Commercial strategy
Licensing future granted patents could generate fees without selling SOULSKIPPER. Income would depend on granted rights, demand and licensing agreements.
Alongside developing the company and possible licensing, eventual acquisition by a larger business is considered an option, potentially allowing investors to participate in created company value.
Potential sectoral connections include Siemens Healthineers in medical technology, diagnostics and digital health; Hitachi High-Tech in medical analytics and healthcare technology; and GE HealthCare in medical technology, monitoring and digital care. GE HealthCare is now independent of General Electric. These examples are the founder's strategic considerations, not evidence of interest, partnerships or acquisition talks. Neither acquisition nor profit is guaranteed.
LJUBOMIR FILIPOVIĆ · Founder, Chief Developer and Chief Executive Officer (CEO) · SOULSKIPPER Limited
ABOUT ME ↗European Patent Office: novelty and grace periods · US Patent Office: disclosure and grace periods · Siemens Healthineers: business areas · Hitachi High-Tech: healthcare · GE HealthCare: business areas · GE HealthCare: independent company
